Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients: Comparisons between Schizophrenia, Bipolar Disorder, and Depression

Schizophrenia Bulletin

Volumn 44, Issue 1, 2018, Pages 75-83

  Wang, Alexandre K ^a   Miller, Brian J ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

bipolar disorder; cerebrospinal fluid; cytokines; inflammation; major depressive disorder; meta analysis; schizophrenia

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; KYNURENIC ACID; TRYPTOPHAN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2;

AMINO ACID BRAIN LEVEL; ARTICLE; BIPOLAR DISORDER; CATABOLISM; COMPARATIVE STUDY; HUMAN; MAJOR DEPRESSION; MENTAL PATIENT; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SCHIZOPHRENIA; SYSTEMATIC REVIEW; CEREBROSPINAL FLUID; INFLAMMATION; META ANALYSIS;

BIPOLAR DISORDER; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; HUMANS; INFLAMMATION; SCHIZOPHRENIA; TRYPTOPHAN;

EID: 85021844910     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbx035     Document Type: Article

References (79)

1. Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci. 2010;8:199-209.
2. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophreniaassociated genetic loci. Nature. 2014;511:421-427.
3. The International Schizophrenia Consortium; Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia that overlaps with bipolar disorder. Nature. 2009;460:748-752.
4. Barbosa IG, Machado-Vieira R, Soares JC, Teixeira AL. The immunology of bipolar disorder. Neuroimmunomodulation. 2014;21:117-122.
5. Ezeoke A, Mellor A, Buckley P, Miller BJ. A systematic quantitative review of blood autoantibody elevations in schizophrenia. Schizophr Res. 2013;150:245-251.
6. Gibney SM, Drexhage HA. Evidence for a dysregulated immune system in the etiology of psychiatric disorders. J Neuroimmune Pharmacol. 2013;8:900-920.
7. Miller BJ, Gassama B, Sebastian D, Buckley P, Mellor A. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2013;73:993-999.
8. Muller N. Immunology of major depression. Neuroimmunomodulation. 2014;21:123-130.
9. Pearlman DM, Najjar S. Meta-analysis of the association between N-methyl-d-aspartate receptor antibodies and schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder. Schizophr Res. 2014;157:249-258.
10. Myint AM. Kynurenines: from the perspective of major psychiatric disorders. FEBS J. 2012;279:1375-1385.
11. Ayorech Z, Tracy DK, Baumeister D, Giaroli G. Taking the fuel out of the fire: evidence for the use of anti-inflammatory agents in the treatment of bipolar disorders. J Affect Disord. 2015;174:467-478.
12. Kohler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and metaanalysis of randomized clinical trials. JAMA Psychiatry. 2014;71:1381-1391.
13. Nitta M, Kishimoto T, Muller N, et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull. 2013;39:1230-1241.
14. Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull. 2014;40:181-191.
15. Florencio-Silva R, Sasso GR, Sasso-Cerri E, Simoes MJ, Cerri PS. Biology of bone tissue, structure, function, and factors that influence bone cells. BioMed Res Int. 2015;2015:421746.
16. Ingman WV, Robertson SA. The essential roles of TGFB1 in reproduction. Cytokine Growth Factor Rev. 2009;20:233-239.
17. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 2009;63:257-265.
18. Hamidi M, Drevets WC, Price JL. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry. 2004;55:563-569.
19. Ongur D, Drevets WC, Price JL. Glial Reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA. 1998;95:13290-13295.
20. Muller N, Weidinger E, Leitner B, Schwarz MJ. The role of inflammation in schizophrenia. Front Neurosci. 2015;9:372.
21. Myint AM, Kim YK. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:304-313.
22. Gaspar PA, Bustamante ML, Silva H, et al. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications. J Neurochem. 2009;111:891-900.
23. Chiappelli J, Pocivavsek A, Nugent KL, et al. Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance. JAMA Psychiatry. 2014;71:761-768.
24. Ravikumar A, Deepadevi KV, Arun P, et al. Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders. Neurology India. 2000;48:231-238.
25. Kegel ME, Bhat M, Skogh E, et al. Imbalanced kynurenine pathway in schizophrenia. Int J Tryptophan Res. 2014;7:15-22.
26. Nilsson LK, Linderholm KR, Engberg G, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res. 2005;80:315-322.
27. Schwieler L, Larsson MK, Skogh E, et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia-significance for activation of the kynurenine pathway. J Psychiatry Neurosci. 2015;2:126-133.
28. Sathyasaikumar KV, Stachowski EK, Wonodi I, et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull. 2011;37:1147-1156.
29. Barry S, Clarke G, Scully P, et al. Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J Psychopharmacol. 2009;23:287-294.
30. Bay-Richter C, Linderholm KR, Lim CK, et al. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-asparate receptor in depression and suicidality. Brain Behav Immun. 2015;43:110-117.
31. Goldsmith D, Rapaport MH, Miller BJ. Meta-analysis of cytokine alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Molecular Psychiatry. 2016;21:1696-1709.
32. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003;60:1187-1192.
33. Barak V, Barak Y, Levine J, Nisman B, Roisman I. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J Basic Clin Physiol Pharmacol. 1995;6:61-69.
34. Carpenter LL, Heninger GR, Malison RT, Tyrka AR, Price LH. Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J Affect Disord. 2004;79:285-289.
35. el-Mallakh RS, Suddath RL, Wyatt RJ. Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry. 1993;17:383-391.
36. Erhardt S, Kim CK, Linderholm KR, et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology. 2013;38:743-752.
37. Garver DL, Tamas RL, Holcomb JA. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology. 2003;28:1515-1520.
38. Hayes LN, Severance EG, Leek JT, et al. Inflammatory molecular signature associated with infectious agents in psychosis. Schizophr Bull. 2014;40:963-972.
39. Isgren A, Jakobsson J, Palsson E, et al. Increased cerebrospinal fluid Interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment. Brain Behav Immun. 2015;43:198-204.
40. Katila H, Hurme M, Wahlbeck K, Appelberg B, Rimon R. Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients. Neuropsychobiology. 1994;30:20-23.
41. Kern S, Skoog I, Borjesson-Hanson A, et al. Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample. Brain Behav Immun. 2014;41:55-58.
42. Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology. 1999;40:171-176.
43. Levine J, Barak Y, Chengappa KRN, Rapoport A, Antelman SM, Barak V. Low CSF soluble interleukin 2 receptor levels in acute depression. J Neural Transm. 1999;106:1011-1015.
44. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry. 1993;150:1408-1410.
45. Linderholm KR, Skogh E, Olsson SK, et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull. 2012;38:426-432.
46. Lindqvist D, Janelidze S, Hagell P, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry. 2009;66:287-292.
47. Lu S. Interleukin level in CSF of patients with first-episode psychosis. Zhongguo Xin Li Wei Sheng Za Zhi. 2003;17:206.
48. Martinez JM, Garakani A, Yehuda R, Gorman JM. Proinflammatory and "resiliency" proteins in the CSF of patients with major depression. Depress Anxiety. 2012;29:32-38.
49. Olsson SK, Samuelsson M, Saetre P, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J Psychiatry Neurosci. 2010;35:195-199.
50. Olsson SK, Sellgren C, Engberg G, Landen M, Erhardt S. Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord. 2012;14:719-726.
51. Palhagen S, Qi H, Martensson B, Walinder J, Granerus AK, Svenningsson P. Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. J Neurol. 2010;257:524-532.
52. Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res. 1997;25:123-129.
53. Sasayama D, Hattori K, Wakabayashi C, et al. Increased cerebrospinal fluid Interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res. 2013;47:401-406.
54. Soderlund J, Schroder J, Nordin C, et al. Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry. 2009;14:1069-1071.
55. Soderlund O, Olsson SK, Samuelsson M, et al. Elevation of cerebrospinal fluid interleukin-1β in bipolar disorder. J Psychiatry Neurosci. 2011;36:114-118.
56. van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK. Elevated interleukin-6 in schizophrenia. Psychiatry Res. 1999;87:129-136.
57. Vawter MP, Dillon-Carter O, Issa F, Wyatt RJ, Freed WJ. Transforming growth factors beta 1 and beta 2 in the cerebrospinal fluid of chronic schizophrenic patients. Neuropsychopharmacology. 1997;16:83-87.
58. Hernandez AV, Guarnizo M, Miranda Y, et al. Association between insulin resistance and breast carcinoma: a systematic review and meta-analysis. PLoS One. 2014;9:e99317.
59. Higgins J, Deeks J. Selecting studies and collecting data. Cochrane Handbook for Systematic Reviews of Interventions Version 510 (updated March 2011) The Cochrane Collaboration. 2001. www.cochrane-handbook.org. Accessed March 8, 2016.
60. Cochran WB. The comparison of percentages in matched samples. Biometrika. 1950;37:256-266.
61. Song F, Sheldon TA, Sutton AJ, Abrams KR, Jones DR. Methods for exploring heterogeneity in meta-analysis. Eval Health Prof. 2001;24:126-151.
62. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. 9.7. Sensitivity analyses. The Cochrane Collaboration. 2011. www.cochrane-handbook.org. Accessed March 8, 2016.
63. Sterne JAC, Egger M. Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis. J Clin Epidemiol. 2001;54:1046-1055.
64. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Brit Med J. 1997;315:629-634.
65. Dellalibera-Joviliano R, Dos Reis ML, Cunha Fde Q, Donadi EA. Kinins and cytokines in plasma and cerebrospinal fluid of patients with neuropsychiatric lupus. J Rheumatol. 2003;30:485-492.
66. Maimone D, Gregory S, Arnason BGW, Reder AT. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol. 1991;32:67-74.
67. Pace TW, Miller AH. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci. 2009;1179:86-105.
68. Thomas R. The TRAF6-NF kappa B signaling pathway in autoimmunity: not just inflammation. Arthritis Res Ther. 2005;7:170-173.
69. Derry HM, Fagundes CP, Andridge R, Glaser R, Malarkey WB, Kiecolt-Glaser JK. Lower subjective social status exaggerates interleukin-6 responses to a laboratory stressor. Psychoneuroendocrinology. 2013;38:2676-2685.
70. Banati R, Hickie IB. Therapeutic signposts: using biomarkers to guide better treatment of schizophrenia and other psychotic disorders. Med J Aust. 2009;190:S26-S32.
71. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med. 2009;50:1801-1807.
72. van Berckel BN, Bossong MG, Boellaard R, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 Positron Emission Tomography Study. Biol Psychiatry. 2008;64:820-822.
73. Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, Kuchel GA. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci. 2008;63:879-884.
74. O'Connor MF, Bower JE, Cho HJ, et al. To assess, to control, to exclude: Effects of biobehavioral factors on circulating inflammatory markers. Brain Behav Immun. 2009;23:887-897.
75. De Berardis D, Conti CM, Serroni N, et al. The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol. 2010;23:417-422.
76. Młodzikowska-Albrecht J, Steinborn B, Zarowski M. Cytokines, epilepsy and epileptic drugs-is there a mutual influence? Pharmacol Rep. 2007;59:129-138.
77. Raghavendra PB, Lee E, Parameswaran N. Regulation of macrophage biology by lithium: a new look at an old drug. J Neuroimmune Pharmacol. 2014;9:277-284.
78. Tourjman V, Kouassi E, Koue ME, et al. Antipsychotics' effects on blood levels of cytokines in schizophrenia: a metaanalysis. Schizophr Res. 2013;151:43-47.
79. Baumeister D, Ciufolini S, Mondelli V. Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment? Psychopharmacology (Berl). 2016;233:1575-1589.